BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miyake K, Nishioka M, Imura S, Batmunkh E, Uto Y, Nagasawa H, Hori H, Shimada M. The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1α targeted gene expression. Exp Cell Res. 2012;318:1554-1563. [PMID: 22472348 DOI: 10.1016/j.yexcr.2012.03.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Chen G, Wu K, Li H, Xia D, He T. Role of hypoxia in the tumor microenvironment and targeted therapy. Front Oncol 2022;12:961637. [DOI: 10.3389/fonc.2022.961637] [Reference Citation Analysis]
2 Hamada S, Matsumoto R, Masamune A. HIF-1 and NRF2; Key Molecules for Malignant Phenotypes of Pancreatic Cancer. Cancers 2022;14:411. [DOI: 10.3390/cancers14020411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
3 Zhang Z, Zhang HJ. Glycometabolic rearrangements-aerobic glycolysis in pancreatic ductal adenocarcinoma (PDAC): roles, regulatory networks, and therapeutic potential. Expert Opin Ther Targets 2021;:1-17. [PMID: 34874212 DOI: 10.1080/14728222.2021.2015321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pirovich DB, Da'dara AA, Skelly PJ. Multifunctional Fructose 1,6-Bisphosphate Aldolase as a Therapeutic Target. Front Mol Biosci 2021;8:719678. [PMID: 34458323 DOI: 10.3389/fmolb.2021.719678] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
5 Curcio C, Brugiapaglia S, Bulfamante S, Follia L, Cappello P, Novelli F. The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer. Molecules 2021;26:1642. [PMID: 33804240 DOI: 10.3390/molecules26061642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, Zhao F, You L, Zheng L, Zhang T, Zhao Y. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol 2021;14:14. [PMID: 33436044 DOI: 10.1186/s13045-020-01030-w] [Cited by in Crossref: 68] [Cited by in F6Publishing: 75] [Article Influence: 34.0] [Reference Citation Analysis]
7 Hu M, Zhang T, Gu M, Li J, Zhang H, Wang Q, Hu F, Yang Y, Li B. Pretreatment to Posttreatment Hypoxia Inducible Factor-1α Ratios as a Potentially Predictive Marker for First-Line Treatment in Nonsmall Cell Lung Cancer Patients without Known Driver Mutations. Genet Test Mol Biomarkers 2020;24:798-803. [PMID: 33347392 DOI: 10.1089/gtmb.2020.0173] [Reference Citation Analysis]
8 Cao L, Wu J, Qu X, Sheng J, Cui M, Liu S, Huang X, Xiang Y, Li B, Zhang X, Cui R. Glycometabolic rearrangements--aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications. J Exp Clin Cancer Res 2020;39:267. [PMID: 33256814 DOI: 10.1186/s13046-020-01765-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
9 Jin X, Dai L, Ma Y, Wang J, Liu Z. Implications of HIF-1α in the tumorigenesis and progression of pancreatic cancer. Cancer Cell Int 2020;20:273. [PMID: 32587480 DOI: 10.1186/s12935-020-01370-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
10 Kaapu KJ, Rantaniemi L, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. Sci Rep 2018;8:10308. [PMID: 29985440 DOI: 10.1038/s41598-018-28541-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Yang XW, Gao F, Chen YJ, Teng FM. The Clinical Study of Urokinase-Type Plasminogen Activator and Vascular Endothelial Growth Factor in Gastric Cancer. Cell Biochem Biophys. 2015;72:649-652. [PMID: 27352182 DOI: 10.1007/s12013-014-0356-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ni JY, Xu LF, Wang WD, Huang QS, Sun HL, Chen YT. Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1α for hepatocellular carcinoma: a preliminary study of rat model. J Cancer Res Clin Oncol 2017;143:199-207. [PMID: 27638772 DOI: 10.1007/s00432-016-2237-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
13 Chan AK, Bruce JI, Siriwardena AK. Glucose metabolic phenotype of pancreatic cancer. World J Gastroenterol 2016; 22(12): 3471-3485 [PMID: 27022229 DOI: 10.3748/wjg.v22.i12.3471] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
14 Cheng G, Sa W, Cao C, Guo L, Hao H, Liu Z, Wang X, Yuan Z. Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions. Front Pharmacol 2016;7:64. [PMID: 27047380 DOI: 10.3389/fphar.2016.00064] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 7.4] [Reference Citation Analysis]
15 He J, Hu Y, Hu M, Zhang S, Li B. The relationship between the preoperative plasma level of HIF-1α and clinic pathological features, prognosis in non-small cell lung cancer. Sci Rep 2016;6:20586. [PMID: 26853843 DOI: 10.1038/srep20586] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
16 Gao C, Li S, Zhao T, Chen J, Ren H, Zhang H, Wang X, Lang M, Liu J, Gao S, Zhao X, Sheng J, Yuan Z, Hao J. SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression. PLoS One 2015;10:e0121338. [PMID: 25799412 DOI: 10.1371/journal.pone.0121338] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
17 Zhang H, Chen J, Liu F, Gao C, Wang X, Zhao T, Liu J, Gao S, Zhao X, Ren H, Hao J. CypA, a gene downstream of HIF-1α, promotes the development of PDAC. PLoS One 2014;9:e92824. [PMID: 24662981 DOI: 10.1371/journal.pone.0092824] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
18 Ghattass K, El-Sitt S, Zibara K, Rayes S, Haddadin MJ, El-Sabban M, Gali-Muhtasib H. The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway. Mol Cancer 2014;13:12. [PMID: 24461075 DOI: 10.1186/1476-4598-13-12] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
19 Ghattass K, El-Sitt S, Zibara K, Rayes S, Haddadin MJ, El-Sabban M, Gali-Muhtasib H. The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway. Mol Cancer 2014;13:12. [PMID: 24461075 DOI: 10.1186/1476-4598-13-12] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Akimoto M, Nagasawa H, Hori H, Uto Y, Honma Y, Takenaga K. An inhibitor of HIF-α subunit expression suppresses hypoxia-induced dedifferentiation of human NSCLC into cancer stem cell-like cells. World J Med Genet 2013; 3(4): 41-54 [DOI: 10.5496/wjmg.v3.i4.41] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
21 Wang SL, Wu R. Progress in research of hypoxia and angiogenesis in pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(30): 3217-3221 [DOI: 10.11569/wcjd.v21.i30.3217] [Reference Citation Analysis]
22 Xu LF, Ni JY, Sun HL, Chen YT, Wu YD. Effects of hypoxia-inducible factor-1α silencing on the proliferation of CBRH-7919 hepatoma cells. World J Gastroenterol 2013; 19(11): 1749-1759 [PMID: 23555163 DOI: 10.3748/wjg.v19.i11.1749] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]